Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P62753
UPID:
RS6_HUMAN
Alternative names:
40S ribosomal protein S6; Phosphoprotein NP33
Alternative UPACC:
P62753; P08227; P10660; Q4VBY7; Q8N6Z7
Background:
Small ribosomal subunit protein eS6, also known as 40S ribosomal protein S6 and Phosphoprotein NP33, is a crucial component of the 40S small ribosomal subunit. It plays a pivotal role in controlling cell growth and proliferation by selectively translating specific classes of mRNA. As part of the SSU processome, it contributes to the assembly of the small eukaryotic ribosomal subunit in the nucleolus, facilitating RNA folding, modifications, rearrangements, and targeted degradation of pre-ribosomal RNA.
Therapeutic significance:
Understanding the role of Small ribosomal subunit protein eS6 could open doors to potential therapeutic strategies.